Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

1
Player Avatar AjarnMichael (45.77) Submitted: 5/9/2010 9:20:16 PM : Underperform Start Price: $3.72 PPHM Score: +140.15

F

Member Avatar AjarnMichael (45.77) Submitted: 6/28/2010 10:56:53 PM
Recs: 0

Might as well buy a lottery ticket. Company has never made a profit and likely never will. Current valuation is abysmal. Best hope is that one of PPHM's products catch the eye of an established pharmaceutical player and they get bought. I wouldn't bet on it.

Featured Broker Partners


Advertisement